Nouscom
Clinical-stage biotech developing neoantigen-based cancer immunotherapies.
€120MSeries D
LeadMV
M Ventures
m-ventures.com ↗Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jul 27, 2026
M Ventures is Merck KGaA’s strategic venture investor in biotechnology, scientific tools, electronics and frontier technology. Explore its recorded Funding activity.
Investment focus
M Ventures is the strategic corporate venture investor of Merck KGaA, Darmstadt, Germany. Its mandate spans drug development, life-science tools, electronics, frontier technology and sustainability. The team combines financial and strategic objectives and works with founders and co-investors to bring scientific and technical developments toward commercial use.
Activity recorded by RoundOS
RoundOS records activity across both sides of that mandate: drug developers Remepy, TwoStep Therapeutics and TRIMTECH; research-tool businesses Lightcast and Vizgen; and optical-interconnect companies Quintessent and Polaris Electro-Optics. These published financing records describe the activity captured here, rather than the firm’s complete portfolio.
Sources
- Rounds participated in
- 3
- Confirmed lead rounds
- 1 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $98.5M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionTwoStep Therapeutics
A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.
$62.5MSeries A
Role not disclosedRemepy
Develops Hybrid Drugs combining prescription medicines with AI-driven therapeutic apps
$36MSeries A
Role not disclosed